| The concept of my country’s medical insurance catalogue was proposed by the former Ministry of Labor and Social Security in 1999,whose full name is called the "National Basic Medical Insurance,Work Injury Insurance and Maternity Insurance Drug Catalog".It is the basis for medical insurance and other social insurance funds to pay for drug expenses and promote the stable development of the pharmaceutical industry.Since the publication of the first edition of the drug catalog in 2000,a total of 4 revisions have been made in 20 years,and the intervals between the revisions are4,5,8 and 2 years respectively.Among them,tumor-targeted drugs were included in the medical insurance catalog management for the first time in 2016.Before targeted drugs were included in the medical insurance catalogue,the overall profit did not match the high R&D costs because they were expensive and targeted at specific populations.But with the economy developing and people paying increasing attention to health as well as the national medical insurance policy adjusted accordingly,the inclusion of targeted drugs in the medical insurance catalog has become an inevitable trend.Its audience has changed from a small group of people who can afford high costs to the market in which the insured are the majority.There is no doubt that its a larger slice of drug market pie.That is to say,this is a blue ocean market for us.However,the entry of targeted drugs into the medical insurance catalogue also means that the price of medicines will be cut in half.At the same time,other targeted drugs with the same efficacy from domestic and foreign pharmaceutical companies have also been included into the medical insurance catalogue.For pharmaceutical companies,it is not only an opportunity but a challenge.At present,domestic researches on the management of pharmaceutical companies are more focused on organizational structure,marketing strategies,etc.,and the research on the medical insurance catalog is mostly focused on the tripartite relationship between the government,hospitals and patients,among which the adjustment of medical insurance catalog and enterprise development are rarely linked.is rarely adjusted.Based on the SWOT analysis theory,EFE/IFE matrix analysis theory and other basic theories,this article analyzes the pros and cons and development strategies of tumor-targeted drugs included in the medical insurance catalog of pharmaceutical companies.Under the major background of the newly established National Medical Insurance Administration and the gradual maturity of targeted drug negotiations,W pharmaceutical companies are used as the research object to study and explore the optimization measures of the company’s business strategy.This article provides a reference direction for the response strategies adopted by W pharmaceutical companies after the new round of medical insurance catalog adjustments,and also provides new theoretical support for other pharmaceutical companies to adapt to the adjustment of medical insurance policy.Based on the empirical analysis of W pharmaceutical companies,on the basis of fully analyzing the advantages and disadvantages of W pharmaceutical companies’ business strategies and the development environment at home and abroad,this paper puts forward the following recommendations to the large domestic innovative pharmaceutical companies including W pharmaceutical companies : In the environment of increasingly fierce competition,to become a strong,better and larger enterprise,we must seize new opportunities for policy dividends and increase R&D efforts.Combining advantages to create competitive products with high technology content and high market scarcity,such as tumor-targeted drugs,and simultaneously improving corporate strategic management can we continue to develop in market competition,and create a first-class pharmaceutical enterprise to produce high-quality and good medicines that the people can use and can afford. |
PDF Full Text Request